Discover
JANX
Janux Therapeutics, Inc.
16.59
2 x 11.53
2 x 20.54
bid
ask
-
0.27
1.60%
2 @ 07:30 PM
16.59 +0.00 (0.00%)
| Ytd | 20.22% | |
| 1y | -32.01% |
16.40
day range
16.86
12.12
52 week range
35.34
| Open | 16.70 | Prev Close | 16.86 | Low | 16.40 | High | 16.86 | Mkt Cap | 1.01B |
| Vol | 2.45M | Avg Vol | 1.03M | EPS | -1.64 | P/E | N/A | Forward P/E | -6.32 |
| Beta | 2.52 | Short Ratio | 8.70 | Inst. Own | 101.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 16.91 | 200-d Avg | 14.95 | 1yr Est | 36.24 |
| Income Statement | |||
| Total Revenue | 10.27M | ||
| Revenues (USD) | 10.27M | ||
| Gross Profit | 10.27M | ||
| Operating Expenses | 41.96M | ||
| Research and Development Expense | 30.99M | ||
| Selling, General and Administrative Expense | 10.96M | ||
| Operating Income | -31.69M | ||
| Net Income | -21.97M | ||
| Net Income Common Stock | -21.97M | ||
| Net Income Common Stock (USD) | -21.97M | ||
| Consolidated Income | -21.97M | ||
| Earnings per Basic Share | -0.35 | ||
| Earnings per Basic Share (USD) | -0.35 | ||
| Earnings per Diluted Share | -0.35 | ||
| Earning Before Interest & Taxes (EBIT) | -21.97M | ||
| Earning Before Interest & Taxes (USD) | -21.97M | ||
| Weighted Average Shares | 62.94M | ||
| Weighted Average Shares Diluted | 62.94M | ||
| Balance Sheet | |||
| Cash and Equivalents | 28.58M | ||
| Cash and Equivalents (USD) | 28.58M | ||
| Investments | 943.15M | ||
| Investments Current | 943.15M | ||
| Trade and Non-Trade Receivables | 149.00K | ||
| Current Assets | 983.34M | ||
| Property, Plant & Equipment Net | 20.59M | ||
| Total Assets | 1.01B | ||
| Debt Current | 2.55M | ||
| Total Debt | 20.99M | ||
| Current Liabilities | 60.15M | ||
| Debt Non-Current | 18.44M | ||
| Total Liabilities | 79.67M | ||
| Accumulated Retained Earnings (Deficit) | -397.71M | ||
| Accumulated Other Comprehensive Income | -2.31M | ||
| Shareholders Equity | 927.98M | ||
| Shareholders Equity (USD) | 927.98M | ||
| Assets Non-Current | 24.32M | ||
| Total Debt (USD) | 20.99M | ||
| Deferred Revenue | 36.15M | ||
| Liabilities Non-Current | 19.52M | ||
| Trade and Non-Trade Payables | 3.02M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 463.00K | ||
| Net Cash Flow from Financing | 2.24M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -24.06M | ||
| Capital Expenditure | -202.00K | ||
| Issuance (Purchase) of Equity Shares | 2.24M | ||
| Net Cash Flow from Investing | -38.78M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -38.58M | ||
| Net Cash Flow from Operations | 12.48M | ||
| Share Based Compensation | 9.06M | ||